Geert J. Groeneveld

Leiden, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 142 publications

Transcranial Magnetic Stimulation as a Translational Biomarker in Early-Phase Anti-Seizure Medication Development: A Randomized, Double-Blind, Placebo-Controlled Study in Generalized Epilepsy.

Transcranial Magnetic Stimulation as a Translational Biomarker in Early-Phase Anti-Seizure Medication Development: A Randomized, Double-Blind, Placebo-Controlled Study in Generalized Epilepsy.

Journal: Clinical pharmacology and therapeutics

Published: January 09, 2026

Respiratory and Antinociceptive Effects of Nociceptin Receptor-µ-Opioid Receptor Agonist Cebranopadol versus Full Opioid Receptor Agonist Oxycodone: A Comparison in Healthy Volunteers.

Respiratory and Antinociceptive Effects of Nociceptin Receptor-µ-Opioid Receptor Agonist Cebranopadol versus Full Opioid Receptor Agonist Oxycodone: A Comparison in Healthy Volunteers.

Journal: Anesthesiology

Published: December 11, 2025

Effects of Selective Sphingosine-1-Phosphate Receptor 1 Agonist, TRV045, on Evoked Pain Tests: An Exploratory, Four-Way Cross-Over Study in Healthy Volunteers.

Effects of Selective Sphingosine-1-Phosphate Receptor 1 Agonist, TRV045, on Evoked Pain Tests: An Exploratory, Four-Way Cross-Over Study in Healthy Volunteers.

Journal: European journal of pain (London, England)

Published: December 10, 2025

A Systematic Review on Disease-Modifying Therapies in Parkinsonian Disorders.

A Systematic Review on Disease-Modifying Therapies in Parkinsonian Disorders.

Journal: Clinical pharmacology and therapeutics

Published: August 08, 2025

Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.

Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.

Journal: Clinical pharmacology and therapeutics

Published: May 21, 2025

Investigational eIF2B activator DNL343 modulates the integrated stress response in preclinical models of TDP-43 pathology and individuals with ALS in a randomized clinical trial.

Investigational eIF2B activator DNL343 modulates the integrated stress response in preclinical models of TDP-43 pathology and individuals with ALS in a randomized clinical trial.

Journal: Nature communications

Published: March 31, 2025

Low-dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug-drug interaction study.

Low-dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug-drug interaction study.

Journal: British journal of clinical pharmacology

Published: December 09, 2024

Application of a Nociceptive Test Battery to Assess Potential Synergy between Two Analgesics in Healthy Subjects.

Application of a Nociceptive Test Battery to Assess Potential Synergy between Two Analgesics in Healthy Subjects.

Journal: ACS pharmacology & translational science

Published: November 28, 2024

Sentinel dosing: A proposed algorithm to guide decision making on which cohorts in early phase clinical pharmacology trials should use this approach.

Sentinel dosing: A proposed algorithm to guide decision making on which cohorts in early phase clinical pharmacology trials should use this approach.

Journal: British journal of clinical pharmacology

Published: September 30, 2024

The impact of a virtual wound on pain sensitivity: insights into the affective dimension of pain.

The impact of a virtual wound on pain sensitivity: insights into the affective dimension of pain.

Journal: Frontiers in pain research (Lausanne, Switzerland)

Published: September 27, 2024

Cognitive Effects of Three β-Adrenoceptor Acting Drugs in Healthy Volunteers and Patients with Parkinson's Disease.

Cognitive Effects of Three β-Adrenoceptor Acting Drugs in Healthy Volunteers and Patients with Parkinson's Disease.

Journal: Journal of Parkinson's disease

Published: August 30, 2024

CB1 Receptor Antagonist Selonabant (ANEB-001) Blocks Acute THC Effects in Healthy Volunteers: A Phase II Randomized Controlled Trial.

CB1 Receptor Antagonist Selonabant (ANEB-001) Blocks Acute THC Effects in Healthy Volunteers: A Phase II Randomized Controlled Trial.

Journal: Clinical pharmacology and therapeutics

Published: August 16, 2024

Showing 1-12 of 142

Last Updated: 09/26/2026